Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-80
SponsorJinling Hospital, China
About this trial
Clinical Study on the Safety and Efficacy of the efficacy and safety of Adebrelimab combined with chemotherapy for neoadjuvant treatment of resectable pancreatic cancer
Eligibility criteria
Qualifiers
Age 18-80 years old, gender unlimited;
Patients with resectable pancreatic adenocarcinoma confirmed by histopathology or cytology (CA19-9 > 150 U/ml);
No previous systemic treatment for pancreatic cancer;
Measurable lesions defined by RECIST standard v1.1 (according to Recist 1.1 standard, the CT scan diameter of tumor lesions is ≥10 mm, and the scan layer thickness is not more than 5 mm);
Disqualifiers
Concurrent with other uncured malignant tumors;
Subjects who have previously used PD-1/PD-L1 antibodies;
Subjects who can be surgically resected or treated with radical radiation;
Subjects with a history of bleeding and any bleeding event with a severity rating of 3 or above on CTCAE4.0 within 4 weeks prior to screening;
Trial design
Treatments tested in this trial
- Adebrelimab
- albumin-bound paclitaxel
- Gemcitabine
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Jinling Hospital, China
Lead sponsor
Jiangsu Hengrui Pharmaceutical Co., Ltd.
Collaborator
Source ClinicalTrials.gov